<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput xmlns:ns2="local" id="7247"><DrugName>gene therapy (hemophilia), Baxter/Vical</DrugName><DrugSynonyms><Name><Value>gene therapy (Factor IX), Vical/Baxter</Value></Name><Name><Value>gene therapy (hemophilia), Baxter/Vical</Value></Name><Name><Value>gene therapy (Factor VIII), Vical/Baxter</Value></Name></DrugSynonyms><CompanyOriginator id="20743">Vical Inc</CompanyOriginator><CompaniesSecondary><Company id="14441">Baxter Healthcare Ltd</Company><Company id="20743">Vical Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="14441" type="Company"><TargetEntity id="5000708777" type="organizationId">Baxter Healthcare Ltd</TargetEntity></SourceEntity><SourceEntity id="20743" type="Company"><TargetEntity id="4295908315" type="organizationId">Vical Inc</TargetEntity></SourceEntity><SourceEntity id="121" type="ciIndication"><TargetEntity id="D66" type="ICD10"></TargetEntity><TargetEntity id="286.0" type="ICD9"></TargetEntity><TargetEntity id="10016080" type="MEDDRA"></TargetEntity><TargetEntity id="D006467" type="MeSH"></TargetEntity><TargetEntity id="-410021453" type="omicsDisease"></TargetEntity><TargetEntity id="330" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1228" type="ciIndication"><TargetEntity id="D67" type="ICD10"></TargetEntity><TargetEntity id="286.1" type="ICD9"></TargetEntity><TargetEntity id="10016077" type="MEDDRA"></TargetEntity><TargetEntity id="D002836" type="MeSH"></TargetEntity><TargetEntity id="-649205375" type="omicsDisease"></TargetEntity><TargetEntity id="331" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="115" type="Action"><TargetEntity id="6964" type="Mechanism">Coagulation Factor VIII Activators</TargetEntity></SourceEntity><SourceEntity id="PTGT-00717" type="ciTarget"><TargetEntity id="99160645521573" type="siTarget">Coagulation factor VIII</TargetEntity><TargetEntity id="4576" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00719" type="ciTarget"><TargetEntity id="8976887821583" type="siTarget">Coagulation factor IX</TargetEntity><TargetEntity id="4611" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="121">Factor VIII deficiency</Indication><Indication id="1228">Factor IX deficiency</Indication></IndicationsSecondary><ActionsPrimary><Action id="115">Factor VIII agonist</Action><Action id="112">Factor IX agonist</Action></ActionsPrimary><ActionsSecondary><Action id="968">Coagulation stimulator</Action><Action id="4778">Gene therapy</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>B2D1</Code><Name>Factor VIII</Name></Ephmra><Ephmra><Code>B2D2</Code><Name>Factors II, VII, IX and X</Name></Ephmra></EphmraCodes><LastModificationDate>2017-09-02T08:55:01.000Z</LastModificationDate><ChangeDateLast>2017-09-26T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Vical and Baxter are no longer codeveloping gene therapies for the treatment of hemophilia [&lt;ulink linkID="316709" linkType="reference"&gt;316709&lt;/ulink&gt;]. Vical entered into a collaborative research agreement with Baxter Healthcare in December 1993 to evaluate the use of Vical's proprietary gene based technology for the treatment of hemophilia. The collaboration focused on the use of gene sequences coding for the human clotting proteins Factor VIII and Factor IX [&lt;ulink linkID="165740" linkType="reference"&gt;165740&lt;/ulink&gt;]. It expired in 1996 without the development of a successful product candidate [&lt;ulink linkID="316709" linkType="reference"&gt;316709&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14441">Baxter Healthcare Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1228">Factor IX deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-03-01T00:00:00.000Z</StatusDate><Source id="316709" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14441">Baxter Healthcare Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="121">Factor VIII deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-03-01T00:00:00.000Z</StatusDate><Source id="316709" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20743">Vical Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1228">Factor IX deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-03-01T00:00:00.000Z</StatusDate><Source id="316709" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20743">Vical Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="121">Factor VIII deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-03-01T00:00:00.000Z</StatusDate><Source id="316709" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14441">Baxter Healthcare Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1228">Factor IX deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1994-12-01T00:00:00.000Z</StatusDate><Source id="165740" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14441">Baxter Healthcare Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="121">Factor VIII deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1994-12-01T00:00:00.000Z</StatusDate><Source id="165740" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20743">Vical Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1228">Factor IX deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1994-12-01T00:00:00.000Z</StatusDate><Source id="177116" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20743">Vical Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="121">Factor VIII deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1994-12-01T00:00:00.000Z</StatusDate><Source id="177116" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00717"><Name>Factor VIII</Name><SwissprotNumbers><Swissprot>O18806</Swissprot><Swissprot>P00451</Swissprot><Swissprot>P12263</Swissprot><Swissprot>Q06194</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00719"><Name>Factor IX</Name><SwissprotNumbers><Swissprot>P00740</Swissprot><Swissprot>P00741</Swissprot><Swissprot>P16293</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="14437">Baxter International Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20743">Vical Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="116893" title="Baxter to obtain option for rights to Vical's 'naked' DNA gene therapy technology"></Deal></Deals><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput>